Erwin R. Boghaert

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert et al. · Science Translational Medicine · 2015 · 530 citations · Full text

Cancer Therapy, Chemoprevention Strategy, Bcl-2/bcl-xl/bcl-w Inhibitor Abt-263 +20

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 354 citations · Full text

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 328 citations · Full text

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert et al. · Molecular Cancer Therapeutics · 2016 · 307 citations

Hematological Malignancy, Tumor Biology, Medicine +11